XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue (Notes) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 04, 2020
Sep. 29, 2019
Oct. 04, 2020
Sep. 29, 2019
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer [Text Block]     Revenue
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical markets, primary end-markets and timing of revenue recognition. The tables also include a reconciliation of the disaggregated revenue with the reportable segments' revenue.
Reportable Segments
Three Months Ended
October 4, 2020September 29, 2019
Discovery & Analytical SolutionsDiagnosticsTotalDiscovery & Analytical SolutionsDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$173,992 $213,347 $387,339 $178,493 $96,759 $275,252 
Europe115,281 198,205 313,486 119,801 70,225 190,026 
Asia134,350 128,850 263,200 128,610 113,035 241,645 
$423,623 $540,402 $964,025 $426,904 $280,019 $706,923 
Primary end-markets
Diagnostics$— $540,402 $540,402 $— $280,019 $280,019 
Life sciences251,929 — 251,929 243,167 — 243,167 
Applied markets171,694 — 171,694 183,737 — 183,737 
$423,623 $540,402 $964,025 $426,904 $280,019 $706,923 
Timing of revenue recognition
Products and services transferred at a point in time$293,460 $518,867 $812,327 $311,123 $259,161 $570,284 
Services transferred over time130,163 21,535 151,698 115,781 20,858 136,639 
$423,623 $540,402 $964,025 $426,904 $280,019 $706,923 
Reportable Segments
Nine Months Ended
October 4, 2020September 29, 2019
Discovery & Analytical SolutionsDiagnosticsTotalDiscovery & Analytical SolutionsDiagnosticsTotal
(In thousands)
Primary geographical markets
Americas$503,490 $475,113 $978,603 $518,884 $300,403 $819,287 
Europe337,435 429,671 767,106 351,216 208,729 559,945 
Asia372,095 310,335 682,430 379,604 319,341 698,945 
$1,213,020 $1,215,119 $2,428,139 $1,249,704 $828,473 $2,078,177 
Primary end-markets
Diagnostics$— $1,215,119 $1,215,119 $— $828,473 $828,473 
Life sciences734,782 — 734,782 702,406 — 702,406 
Applied markets478,238 — 478,238 547,298 — 547,298 
$1,213,020 $1,215,119 $2,428,139 $1,249,704 $828,473 $2,078,177 
Timing of revenue recognition
Products and services transferred at a point in time$827,270 $1,149,166 $1,976,436 $903,274 $765,858 $1,669,132 
Services transferred over time385,750 65,953 451,703 346,430 62,615 409,045 
$1,213,020 $1,215,119 $2,428,139 $1,249,704 $828,473 $2,078,177 

Contract Balances
Contract assets: The unbilled receivables (contract assets) primarily relate to the Company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the consolidated balance sheets. The balance of contract assets as of October 4, 2020 and December 29, 2019 were $35.6 million and $37.0 million, respectively. The amount of unbilled receivables recognized at the beginning of the period that were transferred to trade receivables during the nine months ended October 4, 2020 was $29.5 million. The increase in unbilled receivables during the nine months ended October 4, 2020 as a result of recognition of revenue before billing to customers, excluding amounts transferred to trade receivables during the period, amounted to $28.1 million.
Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related installation for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in "Accounts payable" or long-term in "Long-term liabilities" in the consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The balance of contract liabilities as of October 4, 2020 and December 29, 2019 were $35.0 million and $29.9 million, respectively. The increase in contract liabilities during the nine months ended October 4, 2020 due to cash received, excluding amounts recognized as revenue during the period, was $29.7 million. The amount of revenue recognized during the nine months ended October 4, 2020 that was included in the contract liability balance at the beginning of the period was $24.7 million.
Contract costs: The Company recognizes the incremental costs of obtaining a contract with a customer as an asset if it expects the benefit of those costs to be longer than one year. The Company determined that certain sales incentive programs meet the requirements to be capitalized. Total capitalized costs to obtain a contract were immaterial during the period and are included in other current and long-term assets on the consolidated balance sheets. The Company applies a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the Company's internal sales force compensation program, as the Company determined that annual compensation is commensurate with annual sales activities.
Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized beyond one year in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders and noncancelable software subscriptions and cloud service contracts.
 
Revenue from Contract with Customer, Excluding Assessed Tax $ 964,025 $ 706,923 $ 2,428,139 $ 2,078,177
Transferred at Point in Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 812,327 570,284 1,976,436 1,669,132
Transferred over Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 151,698 136,639 451,703 409,045
Americas [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 387,339 275,252 978,603 819,287
Europe [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 313,486 190,026 767,106 559,945
Asia [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 263,200 241,645 682,430 698,945
Diagnostics [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 540,402 280,019 1,215,119 828,473
Life Sciences [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 251,929 243,167 734,782 702,406
Applied Markets [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 171,694 183,737 478,238 547,298
Discovery & Analytical Solutions [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 423,623 426,904 1,213,020 1,249,704
Discovery & Analytical Solutions [Member] | Transferred at Point in Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 293,460 311,123 827,270 903,274
Discovery & Analytical Solutions [Member] | Transferred over Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 130,163 115,781 385,750 346,430
Discovery & Analytical Solutions [Member] | Americas [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 173,992 178,493 503,490 518,884
Discovery & Analytical Solutions [Member] | Europe [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 115,281 119,801 337,435 351,216
Discovery & Analytical Solutions [Member] | Asia [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 134,350 128,610 372,095 379,604
Discovery & Analytical Solutions [Member] | Diagnostics [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0
Discovery & Analytical Solutions [Member] | Life Sciences [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 251,929 243,167 734,782 702,406
Discovery & Analytical Solutions [Member] | Applied Markets [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 171,694 183,737 478,238 547,298
Diagnostics [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 540,402 280,019 1,215,119 828,473
Diagnostics [Member] | Transferred at Point in Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 518,867 259,161 1,149,166 765,858
Diagnostics [Member] | Transferred over Time [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 21,535 20,858 65,953 62,615
Diagnostics [Member] | Americas [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 213,347 96,759 475,113 300,403
Diagnostics [Member] | Europe [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 198,205 70,225 429,671 208,729
Diagnostics [Member] | Asia [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 128,850 113,035 310,335 319,341
Diagnostics [Member] | Diagnostics [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 540,402 280,019 1,215,119 828,473
Diagnostics [Member] | Life Sciences [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0
Diagnostics [Member] | Applied Markets [Member]        
Disaggregation of Revenue [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 0 $ 0 $ 0 $ 0